Laurus Labs to acquire 60% of Canada’s Galenvs Sciences for $3.75M, boosting oligonucleotide and magnetic nanoparticle capabilities and expanding CDMO offerings. Hyderabad’s Laurus Labs has announced a $3.75 million deal to acquire a 60% stake in Canada-based Galenvs Sciences, aiming to bolster its capabilities in advanced therapeutics and. The Laurus Labs Galenvs acquisition will expand oligonucleotide, magnetic nanoparticle and biotech manufacturing capabilities in India.